Obesity and diabetes are a global epidemic contributing to an increasing prevalence of related systemic disorders, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Nonalcoholic Steatohepatitis (NASH) is a subtype of NAFLD (Nonalcoholic Fatty Liver disease) that is charact...
Find MorePrimary Sjögren syndrome (pSS) is a.prototypical autoimmune.disease. The involvement.of B cells in the pathogenesis.of pSS has long been suspected.on the basis of clinical.observations that include the.presence of serum.autoantibodies, hypergammaglobulinemia, increased.levels of free light chains and.increased risk ...
Find MorePharma giant Celgene finally confirms USD 9 billion Juno Therapeutics buyout Celgene has finally confirmed the week-long rumor of buying Juno Therapeutics for a deal worth around USD 9 billion boosting its Grip in CAR-T therapy domain. A major reason for this buyout is Juno’s lead CAR-T drug candidate JCAR017 that ...
Find MoreAbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a pha...
Find MoreCluster of differentiation 40 or CD40 is a co-stimulatory protein found on the antigen presenting cells of the immune system. Agonistic CD40 molecules which include monoclonal antibodies (mAb) offer a new therapeutic option with the potential to generate anticancer immunity by various mechanisms. CD40 is a TNF recep...
Find MoreEMA to relocate to Amsterdam by March 2019 Results of the Monday's vote for the European Medicines Agency relocation led to the emergence of Amsterdam as the new headquarters, beating the other finalists Milan and Copenhagen. Nineteen European Union member states submitted proposals for the EMA headquarters, and Mil...
Find MoreSevere Combined Immunodeficiency (SCID) is an inherited primary immunodeficiency disease (PIDD) that typically presents in infancy. It is characterized by profound immune deficiency condition resulting in a weak immune system that is unable to fight off even mild infections. Severe Combined Immunodeficiency is a rar...
Find MoreStrategic Immunology Alliance partners Nimbus Therapeutics and Celgene to develop therapies for Autoimmune Disorders A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering into a long-term strategic alliance with Celgen...
Find MoreAnother flop for Alzeimer’s as Late Stage drug of AxovantSciences fails in trial Axovant Sciences has reported the failure of their late-stage trial involving the testing of its pill Intepirdinecould not suppress Alzheimer's symptoms in participants of the trail. The news had plunged the Wall Street into another wav...
Find MoreThrombolytic Sciences announced completion of Phase I TS01 trial A clinical stage vascular health and biotech company, Thrombolytic Science, LLC (TSI), announced the completion of its Phase I trial investigating TS01, which is a new-generation clot-dissolving therapy for the treatment of clot-induced diseases like i...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.